Nature Reviews Urology最新文献

The future of robotic surgery in the age of artificial intelligence. 人工智能时代机器人手术的未来。

IF 14.6 1区医学

Nature Reviews Urology Pub Date : 2026-05-08 DOI: 10.1038/s41585-026-01153-8

Ludovica Cella, Jasmine Lin, Mitchell G Goldenberg, Andrew J Hung

{"title":"The future of robotic surgery in the age of artificial intelligence.","authors":"Ludovica Cella, Jasmine Lin, Mitchell G Goldenberg, Andrew J Hung","doi":"10.1038/s41585-026-01153-8","DOIUrl":"https://doi.org/10.1038/s41585-026-01153-8","url":null,"abstract":"Patient outcomes after robotic surgery vary widely, often reflecting differences in surgical performance. Artificial intelligence (AI) offers new ways to address this variability, with applications spanning automated skills assessment and feedback, intraoperative guidance and autonomous surgery. The most credible short-range advances of AI in this space consist in generating assistive systems that enhance perception, anticipate risks and standardize feedback while remaining under surgeon control. Results from early studies suggest that AI can influence decision-making, reduce errors and shorten learning curves, particularly in areas such as augmented navigation, anatomy recognition, error detection and telesurgery support. Long-term directions include emerging vision-language-action interfaces capable of programming task-specific support through natural language. In addition to technical performance, translation of AI into clinical practice will require robust datasets, systems designed around human users, regulatory alignment and clear accountability. Ultimately, the measure of surgical AI will be patient outcomes, including reduced complications, fast proficiency acquisition and improved outcome consistency across diverse settings.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":14.6,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease. 少转移性前列腺癌-弥合局部和转移性疾病之间的差距。

IF 14.6 1区医学

Nature Reviews Urology Pub Date : 2026-05-06 DOI: 10.1038/s41585-026-01144-9

Alexander Giesen, Julie den Hartog, Jasper Van Goubergen, Kato Rans, Marcella Baldewijns, Thomas Gevaert, Karolien Goffin, Wouter Everaerts, Frank Claessens, Gert De Meerleer, Steven Joniau

{"title":"Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.","authors":"Alexander Giesen, Julie den Hartog, Jasper Van Goubergen, Kato Rans, Marcella Baldewijns, Thomas Gevaert, Karolien Goffin, Wouter Everaerts, Frank Claessens, Gert De Meerleer, Steven Joniau","doi":"10.1038/s41585-026-01144-9","DOIUrl":"https://doi.org/10.1038/s41585-026-01144-9","url":null,"abstract":"The understanding of oligometastatic prostate cancer has advanced substantially in the past two decades, reshaping both diagnostic and therapeutic paradigms. The advent of next-generation imaging, particularly prostate-specific membrane antigen PET-CT, has improved staging accuracy, enabling patients with limited metastatic burden who might benefit from intensified local and metastasis-directed approaches to be identified. Results from randomized phase II trials support the use of metastasis-directed therapy in patients with metachronous oligometastatic prostate cancer. However, evidence for metastasis-directed therapy in de novo presentations remains preliminary but encouraging. In parallel, prostate-directed treatments such as radiotherapy and cytoreductive radical prostatectomy are under active investigation, although the role of these approaches in the era of intensified systemic therapy is yet to be fully defined. Although interest around oligometastatic prostate cancer is growing, several issues are currently unsettled, including a unified definition of oligometastatic prostate cancer; the inclusion of biological information in patient selection; optimal treatment sequencing, including the integration and duration of systemic therapy; and appropriate clinical end points.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":14.6,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing patients with recurrent prostate cancer who refuse ADT. 治疗拒绝ADT治疗的复发性前列腺癌患者。

IF 14.6 1区医学

Nature Reviews Urology Pub Date : 2026-05-05 DOI: 10.1038/s41585-026-01150-x

Kerry R Schaffer, Mark C Markowski

引用次数: 0

HER2 in urothelial cancer: clinical speed outpacing diagnostic clarity. 尿路上皮癌中的HER2：临床速度超过诊断清晰度。

IF 14.6 1区医学

Nature Reviews Urology Pub Date : 2026-05-05 DOI: 10.1038/s41585-026-01151-w

Emanuele Crupi, Filippo Pederzoli, Robert A Huddart, Cheng Liang, Daniele Raggi

引用次数: 0

Adjuvant immunotherapy for renal cell carcinoma: understanding complexity, embracing uncertainty, making a difference. 肾细胞癌的辅助免疫治疗：理解复杂性，拥抱不确定性，有所作为。